Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo-Reference-Cited by-同舟云学术

Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo

Published:2016-11 Issue:8 Volume:12 Page:2341-2351
ISSN:1549-9634
Container-title:Nanomedicine: Nanotechnology, Biology and Medicine
language:en
Short-container-title:Nanomedicine: Nanotechnology, Biology and Medicine

Author:

Evans James C.,Malhotra Meenakshi,Guo Jianfeng,O'Shea Joseph P.,Hanrahan Karen,O'Neill Amanda,Landry William D.,Griffin Brendan T.,Darcy Raphael,Watson R. William,O'Driscoll Caitriona M.

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Materials Science,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering

Reference56 articles.

1. The role of transcription factors in prostate cancer and potential for future RNA interference therapy;Fitzgerald;Expert Opin Ther Targets,2014

2. From guide to target: molecular insights into eukaryotic RNA-interference machinery;Ipsaro;Nat Struct Mol Biol,2015

3. Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?;Guo;Trends Mol Med,2013

4. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?;Guo;Biotechnol Adv,2011

5. Non-viral nucleic acid delivery: key challenges and future directions;Elsabahy;Curr Drug Deliv,2011

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises;International Journal of Molecular Sciences;2024-02-09

2. Nanomedicine-RNAi interface: Architypes in prostate cancer therapeutics;Journal of Drug Delivery Science and Technology;2024-02

3. Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises;2023-11-25

4. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy;Molecular Pharmaceutics;2023-10-24

5. Bioresponsive and multifunctional cyclodextrin-based non-viral nanocomplexes in cancer therapy: Building foundations for gene and drug delivery, immunotherapy and bioimaging;Environmental Research;2023-10